Avinger (NASDAQ:AVGR) Coverage Initiated at StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of Avinger (NASDAQ:AVGR) in a note issued to investors on Saturday. The firm set a “hold” rating on the medical device company’s stock.

Separately, HC Wainwright reissued a “buy” rating and issued a $5.00 target price on shares of Avinger in a research report on Thursday, March 21st.

Avinger Trading Up 2.6 %

AVGR stock opened at $1.68 on Friday. The stock has a market cap of $2.86 million, a P/E ratio of -0.09 and a beta of 1.25. Avinger has a twelve month low of $1.59 and a twelve month high of $18.00. The company’s 50 day moving average is $2.38 and its two-hundred day moving average is $2.93.

Avinger (NASDAQ:AVGR) last announced its quarterly earnings results on Wednesday, May 15th. The medical device company reported ($2.49) EPS for the quarter, missing the consensus estimate of ($1.35) by ($1.14). The company had revenue of $1.86 million for the quarter, compared to analysts’ expectations of $2.36 million. On average, equities research analysts predict that Avinger will post -2.08 earnings per share for the current year.

Avinger Company Profile

Avinger, Inc, a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures.